You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
[68Ga]/[188Re] Complexed [CDTMP] Trans-1,2-Cyclohexyldinitrilotetraphosphonic Acid As a Theranostic Agent for Skeletal Metastases
|
|---|---|
| Published in |
Frontiers in Medicine, June 2017
|
| DOI | 10.3389/fmed.2017.00072 |
| Pubmed ID | |
| Authors |
Ambika P. Jaswal, Virendra K. Meena, Surbhi Prakash, Ankita Pandey, Baljinder Singh, Anil K. Mishra, Puja P. Hazari |
| Abstract |
Metastasis of the osseous tissue is one of the frequent and severe aggravations as a result of several neoplastic conditions, such as metabolic disorders, infections, and cancer. The objective of this study was to evaluate the pertinence of [(68)Ga]-trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid (CDTMP) as a potential bone imaging agent for positron emission tomography (PET) applications as well as to assess [(188)Re]-CDTMP for bone pain palliation in metastatic skeletal disorders. (68)Ga complex of CDTMP was prepared at 80°C at pH 3.5, and (188)Re complex of CDTMP was prepared at room temperature. [(68)Ga]-CDTMP complex was investigated as PET tracer while the therapeutic efficacy was assessed for [(188)Re]-CDTMP. Labeling efficiency, biodistribution, myelotoxicity, and imaging studies were carried out for the complexes synthesized. Both PET and MicroPET imaging studies were performed for [(68)Ga]-CDTMP whereas SPECT acquisitions were acquired for [(188)Re]-CDTMP. Data were analyzed semiquantitatively for all the scintigraphic scans obtained. The radiolabeling efficiency was observed to be >70% for [(68)Ga]-CDTMP. High bone uptake of [(68)Ga]-CDTMP as compared to contralateral tissue was found in PET imaging in Balb/C mice and New Zealand rabbit; the similar result for bone uptake was correlated in the biodistribution study of the compound in BALB/c mice at different time intervals. Biodistribution experiments carried out in mice showed maximum uptake of 6.12 ± 1.22%ID/g at 45 min postinjection. For [(188)Re]-CDTMP, total skeletal uptake was 8.12 ± 1.11%ID/g observed at 1 h postinjection from biodistribution data. High renal uptake confirms renal route of excretion. A good hydroxyapatite binding too was seen for both the complexes. No evidence of destruction or adverse functioning of vital organs was observed for the (188)Re complex. [(68)Ga]-CDTMP complex can be used as a promising PET bone imaging agent and [(188)Re]-CDTMP as a surrogate moiety for therapeutic application. Owing to the short half-life of (68)Ga (68 min), cyclotron-independent radiopharmacy, fast clearance, and rapid renal excretion as evidenced in preclinical animal models. Very low myelotoxicity and highly selective bone uptake prove the potential of [(188)Re]-CDTMP for therapeutic application. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 5 | 29% |
| Researcher | 3 | 18% |
| Student > Doctoral Student | 2 | 12% |
| Student > Master | 1 | 6% |
| Lecturer > Senior Lecturer | 1 | 6% |
| Other | 2 | 12% |
| Unknown | 3 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 5 | 29% |
| Chemistry | 3 | 18% |
| Biochemistry, Genetics and Molecular Biology | 2 | 12% |
| Medicine and Dentistry | 2 | 12% |
| Immunology and Microbiology | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 3 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2017.
All research outputs
#18,554,389
of 22,979,862 outputs
Outputs from Frontiers in Medicine
#3,971
of 5,742 outputs
Outputs of similar age
#241,796
of 317,132 outputs
Outputs of similar age from Frontiers in Medicine
#56
of 70 outputs
Altmetric has tracked 22,979,862 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,742 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.2. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,132 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.